Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

DCTH vs WOK: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DCTH Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–0 Matrix Metrics)

DCTH Overall Winner 6-Pillar Tally: DCTH 6 – 0 WOK Matrix Metrics: DCTH 9 – 0 WOK

As of Nov 16, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over WORK Medical Technology Group LTD Class A (WOK) in the Tradestie Institutional Equity Comparison Engine, winning 9–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DCTH carries a Unified Composite Score of 36.9/100 (SELL) at $19.87 (N/M Forward P/E, 5.2% operating margin), whereas WOK carries 25.6/100 (SELL) at $1.23 (N/M Forward P/E, -41.7% operating margin).

  • Defensive Composite Rating Caution: Although DCTH compares more favorably head-to-head, both DCTH (36.9/100 SELL) and WOK (25.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DCTH vs WOK
DCTH NASDAQ Head-to-Head Winner
Delcath Systems Inc
Surgical & Medical Instruments & Apparatus
$19.87
-3.31% 1D
Market Cap $714.9M
TTM Revenue $110M
Forward P/E N/M
Beta / 30D Vol 1.63β · 131% Vol
Unified Composite Score
36.9 / 100 SELL
Tech 50.0 Fund 35.0 Flow 70.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 66
RSI-14: 66.3 · SMA20: $16.41 · SMA50: $15.95
WOK NASDAQ
WORK Medical Technology Group LTD Class A Ordinary Shares
Surgical & Medical Instruments & Apparatus
$1.23
+2.5% 1D
Market Cap $5.4M
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 38.49β · 153% Vol
Unified Composite Score
25.6 / 100 SELL
Tech 5.0 Fund 39.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 49
RSI-14: 49.1 · SMA20: $1.13 · SMA50: $1.47

6-Pillar Scorecard Institutional Category Breakdown (DCTH 6 – 0 WOK)

Columns: Metric · DCTH · WOK
1. Valuation Multiples DCTH
Forward P/E N/M N/M
Trailing P/E 128.4x N/M
PEG Ratio 1.60x N/M
EV / Revenue 6.0x 0.5x
2. Growth & Scale DCTH
Revenue Growth (YoY) +70.7% +19.1%
Earnings Growth (YoY) +750.0% -95.0%
TTM Revenue (USD) $110M $11M
Market Cap $714.9M $5.4M
3. Profitability & Quality DCTH
Gross Margin 87.6% 17.0%
Operating Margin 5.2% -41.7%
Net Profit Margin 6.0% -41.9%
Return on Equity (ROE) 5.4% -19.2%
4. Balance Sheet & Cash Flow DCTH
Cash Generation (TTM) $20M -$3.4M EBITDA
Cash Flow Margin 18.3% -31.4% EBITDA Mgn
Net Cash / Leverage $53M Net Cash $1855.16 Book/Sh · -19.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DCTH
Options Structure Phase BREAKOUT UNCLASSIFIED
Current IV / %ile 52.1% (20th %ile) N/A (N/A)
Put/Call OI Skew 0.11x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat DCTH
OpEx & R&D Intensity 82.4% of Rev ($91M) 58.7% of Rev ($6.3M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DCTH (9) vs WOK (0)
Institutional Metric DCTH WOK Criterion Row Edge
Market Capitalization
Scale
$714.9M $5.4M Larger Scale DCTH
Trailing P/E Ratio
Valuation
128.4x N/M Lower Multiple DCTH
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+70.7% +19.1% Higher Growth DCTH
Operating Margin (TTM)
Profitability
5.2% -41.7% Higher Margin DCTH
Net Profit Margin
Profitability
6.0% -41.9% Higher Margin DCTH
Return on Equity (ROE)
Capital Efficiency
5.4% -19.2% Higher ROE DCTH
52-Week Range Position
Momentum
82% ($8–$23) 16% ($0–$7) Stronger Trend DCTH
Beta / 30D Volatility
Risk Regime
1.63β · 131% Vol 38.49β · 153% Vol Lower Realized Risk DCTH
Unified Institutional Score
Composite Signal
36.9 / 100 (SELL) 25.6 / 100 (SELL) Higher Composite DCTH
Trailing 12M Revenue (USD)
Operating Scale
$110M $11M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
87.6% 17.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.60x PEG · 6.0x EV/Rev N/M PEG · 0.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$20M ($53M Net Cash) -$3.4M EBITDA ($1855.16 Book/Sh · -19.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DCTH +28.28 pp
DCTH: +41.12% · WOK: +12.84%
3M Horizon DCTH +61.94 pp
DCTH: +17.85% · WOK: -44.09%
6M Horizon WOK +144.51 pp
DCTH: +79.17% · WOK: +223.68%
1Y Horizon DCTH +202.83 pp
DCTH: +130.78% · WOK: -72.05%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DCTH vs WOK. Trailing 12-month operating profitability (DCTH 5.2% vs WOK -41.7%) and valuation multiples (DCTH N/M vs WOK N/M Forward P/E) are benchmarked directly in Pillar 4 below.

DCTH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$110M
Gross Margin87.6%
Op. Margin5.2%
ROE / Fwd P/E5.4% · N/M
WOK ADR TTM Benchmark FX-Normalized USD
TTM Revenue$11M
Gross Margin17.0%
Op. Margin-41.7%
ROE / Fwd P/E-19.2% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DCTH BREAKOUT
66d in phase · OBV ACCUMULATION
Current IV 52.1%
IV Percentile 20th %ile
Put/Call OI Skew 0.11x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact DCTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
WOK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact WOK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DCTH Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $714.9M market capitalization and 5.2% operating margin.
OpEx & R&D Reinvestment 82.4% of Rev ($91M)
90D Engineering Disclosures 0 Published
WOK Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $5.4M market capitalization and -41.7% operating margin.
OpEx & R&D Reinvestment 58.7% of Rev ($6.3M)
90D Engineering Disclosures 0 Published

Investor FAQ DCTH vs WOK Key Questions & Quantitative Answers

As of Nov 16, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over WORK Medical Technology Group LTD Class A (WOK) in the Tradestie Institutional Equity Comparison Engine, winning 9–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DCTH carries a Unified Composite Score of 36.9/100 (SELL) at $19.87 (N/M Forward P/E, 5.2% operating margin), whereas WOK carries 25.6/100 (SELL) at $1.23 (N/M Forward P/E, -41.7% operating margin). Defensive Composite Rating Caution: Although DCTH compares more favorably head-to-head, both DCTH (36.9/100 SELL) and WOK (25.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

DCTH leads the Growth & Scale pillar: DCTH posts +70.7% YoY revenue growth and +750.0% YoY earnings growth on $110M TTM revenue (87.6% gross margin, 5.2% operating margin), compared with WOK at +19.1% YoY revenue growth and -95.0% YoY earnings growth on $11M TTM revenue (17.0% gross margin, -41.7% operating margin). On trailing 12-month operating scale, DCTH generates $110M in USD-normalized revenue versus $11M for WOK. In operating R&D and SG&A reinvestment, DCTH deploys 82.4% of Rev ($91M) (0 90-day corporate R&D disclosures) versus 58.7% of Rev ($6.3M) (0 disclosures) for WOK.

DCTH screens cheaper on headline valuation multiples. DCTH trades at N/M Forward P/E, 128.4x Trailing P/E, 1.60x PEG, and 6.0x EV/Revenue (18.3% FCF margin), whereas WOK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.5x EV/Revenue (-31.4% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DCTH (5.4% ROE) versus WOK (-19.2% ROE) capital efficiency.

In options market volatility and institutional positioning, DCTH carries 52.1% implied volatility (20th %ile, Compressed (<25th %ile)), a 0.11x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.63β · 131% Vol realized risk). By comparison, WOK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (38.49β · 153% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.